Oyster Point Pharma is a clinical-stage pharmaceutical company focused on developing novel therapies for Dry Eye Disease. Its lead candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal spray designed to stimulate the trigeminal parasympathetic pathway and promote natural tear-film production. In Phase 2b studies, patients administered either OC-01 or OC-02 experienced rapid and significant improvements in both signs and symptoms of Dry Eye Disease, and both candidates were well-tolerated with no significant ocular adverse events or drug-related serious adverse events. The company plans to initiate a Phase 3 clinical development program and to advance additional pipeline assets while exploring new treatment areas. Oyster Point will use the $93 million Series B proceeds to support clinical development, explore new treatment areas, and add key talent. The company leverages nicotinic acetylcholine receptor (nAChR) agonists to target receptors on the trigeminal nerve accessible within the nose to activate the Lacrimal Functional Unit. Oyster Point Pharmaceuticals is a San Francisco, CA–based clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat ocular surface disease. Its core programs center on lead compounds targeting dry eye and other ocular surface disorders. The company completed a $22M Series A financing. The round was led by New Enterprise Associates and Versant Ventures. Oyster Point intends to use the proceeds to fund Phase II clinical trials of its lead compounds. Jeffrey Nau, Ph.D., MMS, serves as President and CEO.

Total raised

$115M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2019